

Quality dividends

Dividend-strong value equities with high standards

Open End PERLES on the UBS Global Quality Dividend Payers NTR Index

Investment idea: quality asserts itself

Quality asserts itself in the long term – even on the exchange. Following this basic principle, the UBS Global Quality Dividend Payers Index is banking on 30 selected value equities. This selection occurs quarterly from a global equity universe of more than 3,300 securities. The basic idea behind it is that an investment in selected quality equities should offer a more stable performance compared to the overall market.

Does an attractive dividend yield constitute a value equity?

Value equities are characterized by sustainably profitable business on the part of the respective corporation. Since flourishing companies as a rule distribute an attractive dividend to their shareholders when compared to their sector, a high dividend yield (ratio of dividend to the share price) is generally considered a strong indication of a value equity. Nonetheless, a high dividend yield should not serve separately as the sole selection criterion, because a high dividend yield can also be the result of a previously strong price loss and point to problems in business. In addition, telecommunications securities and utilities, for instance, traditionally boast a relatively high dividend yield, but are not necessarily among the equities with the strongest prospects for growth.

Refined filter process for higher hit rate

The UBS Global Quality Dividend Payers Index therefore provides more selection criteria than just an attractive dividend yield. In order to make the select circle of value-strong index members, each corporation, for instance, has to have a healthy balance sheet, an appealing return on equity as well as sustainable turnover and earnings growth. The set of rules defined by UBS Investment Bank Research also targets a balanced mix with regard to sector and country allocation.

For this, the index portfolio essentially follows the weighting of the much respected MSCI World Index, but on the basis of the assessments of UBS Investment Bank Research may deliberately deviate from this. In this way, on a quarterly basis the UBS



SSPA product type Tracker certificates (1300)

| Currency | Valor | SIX Symbol |
|----------|----------|------------|
| CHF | 18582861 | DIVQC |
| EUR | 18582862 | DIVQE |
| USD | 18582863 | DIVQD |
| | | |

ubs.com/dividenden

Global Quality Dividend Payers Index becomes more strongly geared to those sectors and countries from which the experts expect above-average earnings momentum.

All filter criteria serve a single goal: the long-term prospects of the broadly diversified index portfolio are to be increased to above-average and stable performance. It goes without saying that the UBS Global Quality Dividend Payers Index pursues a net total return approach. That means that the potential dividends of the 30 value equities included are taken into account in the index performance.

The product solution

Open End PERLES on the UBS Global Quality Dividend Payers Index represent a cost-efficient and convenient option for participating permanently in the regularly adjusted and globally diversified quality index with just one transaction.

Opportunities

- Convenient: participation in the UBS Global Quality Dividend Payers Index with just a single transaction.
- Stability: participation in the UBS Global Quality Dividend Payers Index, which due to dividend-strong value equities should boast a more stable performance than the overall market.
- Diversification: the index portfolio is broadly structured with regard to both the sector and the country allocation.
- Expertise: the many years of experience of UBS Investment Bank Research, which has received numerous awards, are reflected in the multitiered equity selection.
- Dividend-strong: net dividends accrued from the corporations contained in the index are reinvested in the respective index.

Risiken

- No capital protection: investors bear the risk of losing the capital invested.
- The issuer intends to see to the liquidity in normal market phases on trading days (over the counter). The sale of a certificate, however, may not always be possible at any given time.
- No currency hedging: possible changes in the currencies in which the equities of the index members are traded against the trading currency of the respective certificate can have a negative impact on the certificate value.
- Systematic risk: the return performance depends on the respective market conditions.
- Each investor bears the general risk that the financial situation of the issuer may worsen. In the event that the issuer becomes insolvent, the products are direct, unsecured and subordinated liabilities of the issuer.

| Open End PERLES in CHF | | |
|-------------------------------|---|--|
| Underlying | UBS Global Quality Dividend Payers Index | |
| Conversion ratio | 1:1 | |
| Management fee | 1.00% p.a. | |
| lssue day | 18 May 2012 | |
| Issue price | CHF 118.25 | |
| ISIN | CH0185828610 | |
| SIX Symbol | DIVQC | |
| Open End PERLES in EUR | | |
| Underlying | UBS Global Quality Dividend Payers Index | |
| Conversion ratio | 1:1 | |
| Management fee | 1.00% p.a. | |
| Issue day | 18 May 2012 | |
| Issue price | CHF 158.46 | |
| ISIN | CH0185828636 | |
| SIX Symbol | DIVQE | |
| Open End PERLES in USD | | |
| Underlying | UBS Global Quality Dividend Payers Index | |
| Conversion ratio | 1:1 | |
| Management fee | 1.00% p.a. | |
| lssue day | 18 May 2012 | |
| Issue price | CHF 156.71 | |
| ISIN | CH0185828628 | |
| SIX Symbol | DIVQD | |

Investor profile

Solutions for investors with experience in stock market topics and structured products and with a medium to increased risk tolerance who would like to participate in the performance of the equities included in the index at little capital and administrative expense.

For other products and information on opportunities and risks visit: **ubs.com/keyinvest**

Disclaimer

This material has been prepared by UBS AG or one of its affiliates ("UBS"). This material is for distribution only as permitted by law. It is not prepared for the needs of any specific recipient. It is published solely for information and is not a solicitation or offer to buy or sell any securities or related financial instruments ("Instruments"). UBS makes no representation or warranty, either express or implied, on the completeness or reliability of the information contained in this document ("Information") except that concerning UBS AG and its affiliates. The Information should not be regarded by recipients as a substitute for using their own judgment. Any opinions expressed in this material may change without notice and may be contrary to opinions expressed by other business areas of UBS as a result of using different assumptions or criteria. UBS is under no obligation to update the Information. UBS, its officers, employees or clients may have or have had an interest in the Instruments and may at any time transact in them. UBS may have or have had a relationship with entities referred to in the Information. Neither UBS nor any of its affiliates, or their officers or employees, accepts any liability for any loss arising from use of the Information.

This presentation is not a basis for entering into a transaction. Any transaction between you and UBS will be subject to the detailed provisions of the term sheet, confirmation or electronic matching systems relating to that transaction. Clients wishing to effect transactions should contact their local sales representative.

This information is communicated by UBS AG and/or its affiliates ("UBS"). * (see below) UBS may from time to time, as principal or agent, have positions in, or may buy or sell, or make a market in any securities, currencies, financial instruments or other assets underlying the product to which this [term sheet / document] relates (the "Structured Product"). UBS may provide investment banking and other services to and/or have officers who serve as directors of the companies referred to in this [term sheet / document]. UBS's trading and/or hedging activities related to the Structured Product may have an impact on the price of the underlying asset and may affect the likelihood that any relevant barrier or relevant trigger event is crossed or triggered. UBS has policies and procedures designed to minimise the risk that officers and employees are influenced by any conflicting interest or duty and that confidential information is improperly disclosed or made available. UBS may pay or receive brokerage or retrocession fees in connection with the Structured Product described herein. In respect of any Structured Product that is a security, UBS may, in certain circumstances, sell the Structured Product to dealers and other financial institutions at a discount to the issue price or rebate to them for their own account some proportion of the issue price. Further information is available on request. Structured Products are complex and may involve a high risk of loss. Prior to purchasing the Structured Product you should consult with your own legal, regulatory, tax, financial and accounting advisors to the extent you consider it necessary, and make your own investment, hedging and trading decisions (including decisions regarding the suitability of the Structured Product) based upon your own judgement and advice from those advisers you consider necessary. Save as otherwise expressly agreed in writing, UBS is not acting as your financial adviser or fiduciary in relation to the Product. UBS generally hedges its exposure to Structured Products, although it may elect not to hedge or to partially hedge any Structured Product. UBS's hedging activity may be conducted through transactions in the underlying asset, index or instrument or in options, futures or other derivatives related to the underlying asset, index or instrument on publicly traded markets or otherwise, and may have an impact on the price of the underlying asset. If a transaction is cash settled, UBS will generally unwind or offset any hedge it has for such Structured Product in close proximity to the relevant valuation time or period. In some cases, this activity may affect the value of the Structured Product. Unless stated otherwise in this document, (i) this document is for information purposes only and should not be construed as an offer, personal recommendation or solicitation to purchase the Structured Product and should not be treated as giving investment advice, and (ii) the terms of any investment in the Structured Product will be exclusively subject to the detailed provisions, including risk considerations, contained in the more detailed legal documentation that relates to the Structured Product (being the confirmation, information memorandum, prospectus or other issuer documentation as relevant). UBS makes no representation or warranty relating to any information herein which is derived from independent sources. This document shall not be copied or reproduced without UBS's prior written permission. In respect of any Structured Product that is a security, no action has been or will be taken in any jurisdiction that would permit a public offering of the Product, save where explicitly stated in the issuer documentation. The Structured Product must be sold in accordance with all applicable selling restrictions in the jurisdictions in which it is sold.

© UBS 2018. All rights reserved. UBS prohibits the forwarding of this information without the approval of UBS.

UBS AG Public Distribution Switzerland P.O. Box, 8098 Zurich keyinvest@ubs.com

ubs.com/keyinvest

Hotline +41-44-239 76 76* Institutional clients +41-44-239 14 66* Intermediaries +41-44-239 77 60* Wealth Management clients +41-44-239 68 00*

*Please note that calls to numbers marked with * may be recorded. When you call these numbers, we assume that you consent to this business practice.

